Diabetes is the most serious and frequently diagnosed metabolic disease. Declared pandemic by the WHO, it is a major risk factor for morbidity and mortality. Many short and long term complications are associated with this disease. Today, 10% of the world’s population has Diabetes..
- We have researched and developed innovative treatment of Diabetes.
- We treat insulin-dependent, chronic diabetic patients with type 1 or type 2 diabetes with low c-peptide and the need to increase insulin dose for metabolic stabilization.
- This clinical situation is a big problem and a great challenge for everyone because these patients have a high risk of complications.
Our WIPO Patent and Protocol of Bone Marrow Stem Cells Auto transplant, without cell cultures or immunosuppression, but with a different indication, is our first stage of development.
Since 2000, we have known that bone marrow stem cells have Anti-inflammatory, Immunomodulatory and Regenerative capabilities. Several studies have noted the regenerative capacity of stem cells present in all tissues. The mechanism of action of stem cells is knowledge, whereby the tissue secretes chemokines which triggers-migration, stimulation, aggregation and differentiation of the stem cells activated with the aim of achieving tissue regeneration and specific cell function or differentiation in to specialized cells of different biological lines.
- We have many preclinical antecedents of bone marrow stem cells migration, and differentiation into B cells with insulin production.
How is the treatment performed?
The medical team includes the patient in the protocol of treatment. Filgrastim is used to stimulate and increase the number of stem cells in the bone marrow of the patient. Harvesting is performed using a fine needle, in a sterile, special procedure room, under sedation, from the hip of the patient. The sample is processed and immediately injected back into the patient. The extraction procedure of bone marrow and implantation takes approximately one hour of surgical time (while under sedation). Discharge from the clinic takes place two hours later. No complication or Serious adverse events were reported. One needs to stay in Nassau 7 days to complete the treatment.
What is the treatment outcome?
Within four months after treatment, 80% of patients report a significant improvement in the clinical and metabolic condition, no-pain or complications, and an improved quality of life and significant reduction in the quantity of daily insulin dose. Some patients have complete remissions (Normalize the c peptide, A1c Hemoglobine and Insulin secretion) and do not require any medication. This clinical evolution is prolonged and maintained over time (5 years).
What Scientific Evidence has been completed?
These results were reported in our publications and replicated and confirmed by three important Meta-analyses that analyzed more than 2.000 patients.
Our follow-up protocol involves clinical control every three months (symptoms, daily dose of insulin, events) and blood tests (peptide c, glycosylated hemoglobin, fasting blood glucose). If possible, the patients should return to Nassau at six months of follow up.
- The treatment protocol has no complications or adverse events because we use the patient’s own cells, thus rejection is not possible.
- Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A MetaAnalysis. PLOS ONE | DOI:10.1371/journal.pone.0151938 April 13, 2016 (Click here to download)
- Clinical efficacy of autologous stem cell transplantation for the treatment of patients with type 2 diabetes mellitus: a meta-analysis. Cytotherapy, July 2015. Volume 17, Issue 7 (Click here to download)
- Evaluation of the clinical efficacy of stem cell transplantation in patients with type 1 diabetes mellitus. Jun-Xia Cao1, Yu-Qing Zhao2, Gui-Chun Ding3, Int J Clin Exp Med 2016;9(10):19034-19051 (Click here to download)
- Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: Preliminary results. Med Sci Monit. 2013; 19: 852–857 (Click here to download)
- C-peptide increase in chronic type 1 diabetic patients treated with autologous bone marrow cell transplantation through pancreatic artery catheterization: Three years follow-up. SCD> Vol.3 No.1, January 2013 (Click here to download)